INCRHealthcare · Drug Manufacturers - Specialty & Generic

INCR Stock Forecast: InterCure Ltd. Price Predictions for 2026-2027

Last close, 24 Aug 2026

$5.48

+543.57% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap

$50.4M

Ticker Nerd rank

12 / 100

Median analyst target

—

Analysts covering

Revenue$102.4M+7.5% y/y

Operating income$6.7M

Net income$3.7M

Quarterly, 5 quarters to 30 June 2023 · latest quarter's figure shown

Total return, dividends reinvested

+478.1%

+467.3%

YTD

+502.2%

+226.2%

From 52W high

0.0%

From 52W low

+650.7%

$0.73

$5.48

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

INCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InterCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility

Size

Value

Momentum

Accruals

Revisions

Quality

Issuance

Growth

Volatility (88): The share price has been relatively steady.

Growth (1): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts

8 Buy4 Hold0 Sell

Recent analyst actionsNewest first

Of the 11 most recent actions, 5 moved their price target up and 5 moved it down.

Date	Firm	Action	Rating	Target
12 Apr 2023	TD Cowen	Maintains	Outperform	$10 → $5.00
11 Dec 2017	Barclays	Initiates	Equal-Weight	$40
14 Nov 2017	Credit Suisse	Maintains	Outperform	$68 → $54
13 Nov 2017	Keybanc	Maintains	Overweight	$68 → $46
10 Nov 2017	Baird	Maintains	Outperform	$67 → $46
17 Aug 2016	Jefferies	Maintains	Buy	$56 → $55
12 Aug 2016	Goldman Sachs	Maintains	Buy	$60 → $62
18 Apr 2016	Avondale Partners	Maintains	Market Perform	$39 → $47
1 Sept 2015	Jefferies	Upgrade	Buy	$50 → $51
27 May 2015	Jefferies	Maintains	Hold	$35 → $37
12 Feb 2015	Baird	Upgrade	Outperform	$26 → $29

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCR appears on the weeks it earns a place.

Performance

INCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, InterCure Ltd. returned +226.2% against +19.6% for the S&P 500, dividends included.

INCR vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

InterCure Ltd. (INCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 22.2×
Price / sales: 0.2×
Price / book: 0.1×
EV / EBITDA: 8.8×

Growth & margins

Revenue growth (YoY): 23.9%
Earnings growth (YoY): 7.5%
Gross margin: 31.9%
Operating margin: −9.0%
Net margin: −13.2%

Returns & dividend

Return on equity: −9.3%
Return on assets: −5.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InterCure Ltd. (INCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

InterCure Ltd. has a market value of $50.4M and an enterprise value of $187.0M.
Revenue in the twelve months to 30 June 2023: $414.8M. The latest quarter grew 23.9% year on year.
Net income over the same four quarters: $17.4M, a 4.2% net margin.
Shares outstanding: 54.7M.
Trailing P/E: 22.2×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
InterCure Ltd. employs 285 people — $1.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2023 · market figures as at 23 Aug 2026

Data provided by Twelve Data

Peers

INCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
INCRInterCure Ltd.	$50.4M	12
SCYXSCYNEXIS, Inc.	$50.6M	43
TLPHTalphera, Inc.	$59.6M	42
ZYBTZhengye Biotechnology Holding Ltd.	$60.6M	47
IXHLIncannex Healthcare, Inc.	$42.7M	23
CPHIChina Pharma Holdings, Inc.	$42.2M	50
CTORCitius Oncology, Inc.	$69.2M	15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InterCure Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INCR news & analysis

InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages

GlobeNewsWire · 24 Aug 2026positive

InterCure Ltd. finalized a NIS 230 million (~US$77 million) settlement related to indirect damages from the war. The company plans to use these funds to accelerate rehabilitation of Canndoc's flagship Nir Oz facility, aiming to return to full production and support expansion in the German medical cannabis market.

Why it matters — The settlement provides InterCure with a substantial cash influx that could help restore its key production facility and strengthen its position in the growing German medical cannabis market.

FAQ

Frequently asked questions about INCR stock

Is INCR stock a buy right now?

Of the 12 analysts covering InterCure Ltd., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InterCure Ltd. 12 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INCR?

As at 22 Aug 2026, InterCure Ltd. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (88 of 100).

What is the INCR stock forecast for 2030?

No analyst covering InterCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCR are extrapolating price history, which says nothing about the business.

How has INCR stock performed over the past year?

InterCure Ltd. returned +226.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InterCure Ltd. do?

Intercure Ltd. is a leading pharmaceutical company focused on the development, production, and distribution of cannabis-based products.

What is the latest news on INCR?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages". InterCure Ltd. finalized a NIS 230 million (~US$77 million) settlement related to indirect damages from the war. The company plans to use these funds to accelerate rehabilitation of Canndoc's flagship Nir Oz facility, aiming to return to full production and support expansion in the German medical cannabis market.

Company

About InterCure Ltd.

Intercure Ltd. is a leading pharmaceutical company focused on the development, production, and distribution of cannabis-based products. It stands at the forefront of the medical cannabis industry, leveraging advanced cultivation techniques and proprietary R&D to provide high-quality treatments for a range of medical conditions. Intercure's extensive portfolio includes both therapeutic and wellness products designed to meet the needs of patients and healthcare providers. The company is engaged in several strategic partnerships and collaborations with global leaders in the pharmaceutical and wellness sectors, enhancing its market reach and innovation capabilities. Intercure's operations and distribution networks span multiple countries, positioning it as a key player in the rapidly evolving cannabis market. Through its commitment to rigorous scientific research and regulatory compliance, Intercure is instrumental in advancing the acceptance and integration of medical cannabis into mainstream healthcare solutions. Its active participation in clinical studies and contribution to cannabinoid pharmacology underscores its significant role in the field, supporting informed decisions and elevating health outcomes.

CEO Mr. Alexander Rabinovich · 285 employees · Israel · https://www.intercure.co